Top 10 Global Pharma Companies 2022
COVID-19 vaccines and treatments continue to make headline news and bring in huge revenues for sponsor companies, but Pharma Exec’s 2022 Top 50 Companies ranking suggests that many non-COVID products…
Patrick is the managing editor of PharmaBoardroom, writing and editing stories on all things healthcare and the life sciences. The holder of a Master's Degree in International Relations, Patrick has contributed to over 40 country reports and is a fluent Mandarin speaker.
COVID-19 vaccines and treatments continue to make headline news and bring in huge revenues for sponsor companies, but Pharma Exec’s 2022 Top 50 Companies ranking suggests that many non-COVID products…
Talent and manpower are crucial elements in healthcare transformation, from trained clinicians to nurses, technical experts, and managers, but the GCC’s particularities create unique challenges in this regard. A full…
SK Bioscience’s announcement that the first batch of its domestically developed COVID vaccine has been shipped may mark a significant milestone in South Korea’s journey towards greater vaccine self-sufficiency. …
Italy, Europe’s fourth largest pharma market at a size of EUR 23.446 billion, has a highly decentralised healthcare system, with the country’s 20 regions negotiating market access for medicines individually…
Some of the most important stories emanating from the Central and Eastern European (CEE) region’s pharma industry, including Poland’s most promising biotech start-ups, an interview with Zentiva CEO Nick Haggar,…
US generics giant Mallinckrodt, which declared bankruptcy in 2020 after a stream of litigation regarding its role in the opioid epidemic and underpaying Medicaid rebates for its drug Acthar, has…
Some of the most significant recent stories emanating from Chinese healthcare and life sciences, including why the development of a domestic mRNA COVID vaccine – widely acknowledged as an essential…
US biotech Moderna – producer of a messenger RNA (mRNA) COVID-19 vaccine that has found its way into 75 million arms in the US alone and generated USD 12 billion…
When the COVID-19 pandemic struck in early 2020, Europe’s reliance on active pharmaceutical ingredient (API) and generic medicine suppliers outside of the continent was laid bare. In the face of…
As China struggles to maintain its ‘dynamic zero-COVID’ policy in the face of Omicron variant outbreaks, other key talking points emerging from the world’s second-largest healthcare and life sciences market…
Japanese firm Kirin, part of the Mitsubishi Group and best known for its brewing operations, has pledged to invest JPY 100 billion (USD 870 million) into its healthcare/pharma operations amid…
A roundup of the latest news from Japanese pharma, including Kirin’s USD 870 million investment in its healthcare and pharmaceuticals businesses over the next three years, Sanofi’s world-first approval for…
See our Cookie Privacy Policy Here
